» Articles » PMID: 12672030

Tenascin-C Upregulates Matrix Metalloproteinase-9 in Breast Cancer Cells: Direct and Synergistic Effects with Transforming Growth Factor Beta1

Overview
Journal Int J Cancer
Specialty Oncology
Date 2003 Apr 3
PMID 12672030
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Tenascin-C (TN-C) and matrix metalloproteinases (MMPs) are highly expressed in cancer tissues and probably promote cell migration during cancer progression. TN-C and MMPs are often co-localized in areas of active tissue remodeling in pathologic conditions, suggesting reciprocal regulation. To investigate whether TN-C regulates MMPs expression in cancer cells, we first exposed mammary cancer cells derived from TN-C-deficient mice to TN-C and examined MMPs expression. TN-C was then compared with fibronectin (FN), laminin (LN), basic fibroblast growth factor (b-FGF) and transforming growth factor-beta1 (TGF-beta1). Results of endpoint RT-PCR, quantitative real-time RT-PCR and gelatin zymography demonstrated that TN-C, strongly and dose dependently, upregulates MMP-9 expression in murine mammary cancer cells. TN-C weakly induced MMP-2, MMP-3 and MMP-13. FN and LN induced MMP-9 to lesser extents compared with TN-C. b-FGF had no effect on MMP-9 expression. TGF-beta1 induced MMP-9 expression in a dose-dependent manner, and this induction was significantly enhanced by addition of TN-C. TN-C and TGF-beta1 also upregulated MMP-9 expression in the human breast cancer cell line MDA-MB-231. Neutralization with specific anti-TGF-beta1 antibody showed decreased expression of MMP-9, indicating that TGF-beta controls the baseline MMP-9 expression by a direct autocrine mechanism. Under neutralization of TGF-beta, addition of TN-C still upregulated MMP-9. Conversely, neutralization of endogenous TN-C (in a TN-C-positive mammary cancer cell line) downregulated TGF-beta-induced MMP-9 expression. Thus, TN-C induces MMP-9 expression directly and by collaboration with TGF-beta. These findings reveal a novel role of TN-C in breast cancer progression.

Citing Articles

Negative regulation of lymphangiogenesis by Tenascin-C delays the resolution of inflammation.

Katoh D, Senga Y, Mizutani K, Maruyama K, Yamakawa D, Yamamuro T iScience. 2025; 28(2):111756.

PMID: 39925433 PMC: 11803235. DOI: 10.1016/j.isci.2025.111756.


Tenascin-C-Matrix Metalloproteinase-3 Phenotype and the Risk of Tendinopathy in High-Performance Athletes: A Case-Control Study.

Lopes L, Amaral M, Goes R, Tavares V, Dias F, Medeiros R Diagnostics (Basel). 2024; 14(22).

PMID: 39594135 PMC: 11592874. DOI: 10.3390/diagnostics14222469.


Fluoroquinolones Suppress TGF-β and PMA-Induced MMP-9 Production in Cancer Cells: Implications in Repurposing Quinolone Antibiotics for Cancer Treatment.

Huang C, Yang J, Chen J, Tai S, Yeh Y, Liu P Int J Mol Sci. 2021; 22(21).

PMID: 34769032 PMC: 8584204. DOI: 10.3390/ijms222111602.


Extracellular Matrix Derived from High Metastatic Human Breast Cancer Triggers Epithelial-Mesenchymal Transition in Epithelial Breast Cancer Cells through αvβ3 Integrin.

M Brandao-Costa R, Helal-Neto E, M Vieira A, Barcellos-de-Souza P, Morgado-Diaz J, Barja-Fidalgo C Int J Mol Sci. 2020; 21(8).

PMID: 32340328 PMC: 7216035. DOI: 10.3390/ijms21082995.


IL-33/ST2 axis promotes glioblastoma cell invasion by accumulating tenascin-C.

Zhang J, Tao T, Wang K, Zhang G, Yan Y, Lin H Sci Rep. 2020; 9(1):20276.

PMID: 31889095 PMC: 6937274. DOI: 10.1038/s41598-019-56696-1.